Hu5F9 G4

Drug Profile

Hu5F9 G4

Alternative Names: Hu5F9G4

Latest Information Update: 08 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Stanford University
  • Developer Forty Seven; Stanford University
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action CD47 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Colorectal cancer; Diffuse large B cell lymphoma; Non-Hodgkin's lymphoma; Solid tumours
  • Phase I Acute myeloid leukaemia; Myelodysplastic syndromes

Most Recent Events

  • 06 Dec 2017 Phase-I clinical trials in Acute myeloid leukaemia (First-line therapy, Combination therapy) in USA (Parenteral)
  • 06 Dec 2017 Phase-I clinical trials in Acute myeloid leukaemia (Second-line therapy or greater, Monotherapy) in USA (Parenteral)
  • 06 Dec 2017 Phase-I clinical trials in Myelodysplastic syndromes (Combination therapy, First-line therapy) in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top